Primary Care Clinical Pharmacy M&A in 2026

Managed clinical pharmacy providers have established an important position within primary care, predominantly through services funded by the Additional Roles Reimbursement Scheme (ARRS) and delivered to Primary Care Networks (PCNs) and GP practices. Alongside the deployment of clinical pharmacists and pharmacy technicians, they organise recruitment, training, clinical supervision and continuity of service. Their development has created a market for outsourced clinical delivery that sits between traditional recruitment and the provision of broader healthcare services.

The sector has also attracted a range of acquirers and investors. Recent transactions show businesses combining clinical pharmacy delivery with professional education, pharmaceutical industry services and digital long-term condition management. These combinations suggest that clinical pharmacy is becoming part of a broader healthcare services market, with buyer interest extending beyond the supply of workforce capacity.

ARRS remains central to the market in England. Its scale supports an established customer base, but a larger workforce funding pot does not guarantee a growing allocation to clinical pharmacy services. Operators therefore face two connected questions: how to strengthen their position within primary care, and how far their existing capabilities can support revenue from other budgets and customers.

The development of managed clinical pharmacy services

The commercial importance of the managed service model lies in the responsibility providers assume for delivery. A recruitment business principally solves a staffing requirement. A managed provider combines clinical capacity with supervision, governance and continuity across a contract. For acquirers, the attraction is an established service platform and ongoing customer relationships, alongside access to clinicians.

Clinical scope varies between providers, but the strength of the proposition depends on what it delivers in practice: supervision that clinicians can access, reliable cover, consistent systems and a clear relationship with the practice team.

Remote and hybrid delivery can widen recruitment reach and support scale, but are increasingly features of the market rather than sufficient differentiation in themselves. The stronger commercial distinction is a provider’s ability to maintain service quality and retain customers as its clinical capacity grows.

The wider policy direction remains supportive. England's 10 Year Health Plan prioritises care in the community, prevention and greater use of digital tools. Clinical pharmacy fits that direction, particularly where services improve medicines management or release capacity for other clinicians. The extent to which this translates into growth will depend on commissioning priorities and available budgets.

ARRS funding and competition for allocations

The Additional Roles Reimbursement Scheme has helped establish multidisciplinary teams within general practice. Its funding has grown substantially: NHS England set total ARRS funding at £1.412 billion for 2023/24, while its 2026/27 guidance specifies national workforce funding of approximately £1.768 billion. These are nominal funding envelopes, rather than actual expenditure on outsourced clinical pharmacy services. Changes in eligible roles also mean the figures are not a like-for-like measure of support for clinical pharmacists.

For 2026/27, a PCN's allocation is calculated using £27.668 per weighted patient. A network with a weighted population of 50,000 therefore has an indicative annual allocation of £1.383 million. That funding supports eligible workforce roles across the network. It is not a dedicated clinical pharmacy budget or a measure of the revenue available to external providers.

The scheme has become more flexible. In 2025/26, GP funding was brought into the main ARRS envelope and practice nurses became eligible. For 2026/27, the restriction to recently qualified GPs was removed, subject to other eligibility conditions, and greater flexibility was introduced for roles agreed with the commissioner.

Two risks follow. First, providers depend on the continued availability and structure of ARRS funding. Second, they compete for allocations within it. A PCN can change its workforce priorities even when the national pot grows, allocating more to GPs, nurses or other clinicians. The risk to a provider can therefore arise locally without a national funding cut.

The current evidence supports continued investment in additional primary care roles. It does not justify assuming that ARRS will disappear, or that its present structure will remain indefinitely. The scheme is reviewed through the GP contract, and providers cannot control future policy choices.

For operators, this increases the importance of showing the value of their clinical pharmacy team relative to other uses of a customer's budget. It also makes funding diversification a commercial issue even where customers are satisfied and contracts are performing well. A successful ARRS-supported service can remain attractive while carrying a material concentration of external funding risk.

ARRS analysis in this report relates to England. The other UK nations have different primary care structures and funding arrangements, which should be assessed separately when considering expansion.

Competitive environment

The provider market includes regional operators, businesses specialising in remote delivery and groups with broader clinical services. This fragmentation creates scope for consolidation, particularly where acquisitions can add customers and clinical capacity to an existing delivery platform.

Public information does not support a reliable market-share ranking. Employee counts are affected by the use of employed and contracted clinicians, while customer numbers can encompass contracts of very different scope. Clinical capacity, contract coverage and customer retention provide a more useful basis for assessing scale than any single headline measure.

There is a clear adjacency with First Contact Practitioner (FCP) services. Clinical pharmacy and FCP providers share primary care customers and require similar mobilisation and service management infrastructure, yet crossover between specialist providers appears limited. This creates a potential rationale for combinations, subject to each discipline retaining appropriate clinical leadership. Where both services rely on ARRS, a broader offering would still be exposed to the same funding allocation.

What recent transactions tell us

M&A interest predates Agentis' acquisition of Clinical Pharmacist Solutions in August 2026. Transactions since 2020 show several routes into the market, including pharmaceutical services, healthcare workforce businesses and established pharmacy groups. Investments in FCP providers add relevant evidence of interest in managed primary care delivery, although they are not direct valuation comparators.

Date	Business	Acquirer or investor	Transaction
Jul 2020	Interface Clinical Services	IQVIA	Acquisition of clinical pharmacy services business.
Dec 2021	Firza	Ashtons, now Agentis	Acquisition of primary care clinical pharmacy provider.
Sep 2022	Medacy	CHASE	Acquisition of clinical pharmacist-led NHS services provider.
Sep 2023	Primary Care Physio, now Promni Health	BGF	£8.25m investment in managed primary care services.
Oct 2024	Medicines Management Solutions	Pharmacy2U	Acquisition of managed medicines services business.
Oct 2024	Unity Health Group, including Pure Physiotherapy	ExamWorks UK	Acquisition of group spanning physiotherapy and adjacent services.
May 2025	The Pharmacist Network Group and MORPh	Growth Fund 1	Investment supporting combination of clinical services and education.
Aug 2025	Sano Physiotherapy	Bestport	Investment in physiotherapy and rehabilitation provider.
Sep 2025	Living With	Agentis	Acquisition of remote patient management platform.
Aug 2026	Clinical Pharmacist Solutions	Agentis	Acquisition of clinical services, recruitment and training provider.

How M&A is reshaping the market

The transaction record points to two connected developments: consolidation among clinical service providers and their combination with businesses that bring different capabilities or customer relationships. In our view, both are likely to influence the next phase of the market's development.

Consolidation within clinical pharmacy has a straightforward commercial rationale. An established provider can acquire additional customers and clinical capacity while sharing recruitment, supervision and account management infrastructure. Agentis' acquisitions of Firza and Clinical Pharmacist Solutions illustrate the assembly of a broader clinical pharmacy offering. The benefit depends on how well the services can be integrated. Combining customer bases alone does not guarantee more efficient delivery or stronger customer retention.

Other transactions show buyers connecting clinical pharmacy with complementary activities and funding models. IQVIA's acquisition of Interface Clinical Services illustrates the relevance of clinical delivery to pharmaceutical services groups: Interface's offering includes clinical review programmes funded by industry. CHASE positioned its acquisition of Medacy around strengthening collaborative working between the pharmaceutical industry and the NHS. Medacy combines ARRS-funded PCN services with NHS–industry partnership programmes delivered alongside CHASE. The combination of The Pharmacist Network and MORPh brings clinical delivery together with professional education and pharmaceutical industry services, while Agentis' acquisition of Living With adds remote patient management technology. Each combination builds a wider service proposition around clinical delivery.

This helps explain why the potential buyer population extends beyond direct competitors. For a healthcare workforce business, a managed clinical pharmacy service can add responsibility for ongoing clinical delivery. For a group serving the pharmaceutical industry, it can provide the capability to implement programmes within the NHS. Pharmacy2U's acquisition of Medicines Management Solutions also demonstrates interest from a group with established online pharmacy and dispensing activities. The strategic relevance of a provider therefore depends partly on what it adds to an acquirer's existing activities.

The implications for funding are equally important. A broader service range can create relationships with customers whose budgets are separate from PCN workforce allocations. It can also leave the underlying funding exposure largely intact. Combining clinical pharmacy services with another ARRS-funded profession increases the range of services available to a PCN, while retaining reliance on the same allocation. Transactions should therefore be assessed through the resulting mix of customers and revenues, alongside the capabilities acquired.

Investment in FCP providers demonstrates interest in managed primary care delivery beyond clinical pharmacy. Shared customers and service infrastructure offer a commercial rationale for combinations across professions, although integration requires distinct clinical leadership and delivery expertise.

What this means for future M&A

Clinical pharmacy services sit at the intersection of several attractive market themes: pressure on general practice capacity, care moving into the community and demand for better medicines management. The transaction record shows that these services can attract interest from both specialist providers and groups with broader healthcare activities.

Funding concentration will remain a factor in buyer appetite. A provider can have satisfied customers and recurring contracts while depending heavily on one policy framework. Our view is that buyers are likely to assess both the sustainability of the national funding envelope and the provider's ability to retain its share of local allocations. Growth in the overall ARRS pot does not remove those questions.

Acquirers will also differ in what they value. A direct competitor may prioritise customers and clinical capacity. A pharmaceutical services group may place greater weight on NHS relationships and the ability to deliver defined clinical programmes. A broader healthcare group may be interested in an established platform for managed primary care delivery. Buyer appetite will therefore reflect the capabilities a provider adds to the wider group, alongside its standalone scale.

We expect further consolidation, supported by the fragmented provider population and the range of combinations already demonstrated. It is likely to be selective. Clinical pharmacy providers will differ in their customer relationships, delivery models and funding exposure, and those differences will shape which buyers find them attractive. The emerging market is broader than outsourced clinical pharmacist deployment, but the quality of clinical delivery remains central to its commercial value.